ONCY

Yeh

 

Updating the market on its flagship immunotherapeutic agent pelareorep, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) laid out its primary breast cancer achievements in 2021, as well as its 2022 program to come in its latest letter to shareholders.

For breast cancer patients treated with pelareorep Oncolytics has witnessed a more-than-doubling of overall survival in metastatic HR+/HER2- in IND-213--as seen from study results delivered in 2017.

Through a series of data analysis, Oncolytics chose to focus on the three achievable objectives put in place by regulators and the company's pharma partners, representing important steps towards a registrational study. This included: 1. Confirming that pelareorep works through an immunotherapeutic mechanism of action; 2. Determining whether pelareorep synergizes with immune checkpoint inhibitors; and 3. Identifying a biomarker to select patients who are likely to have better clinical outcomes.

In the shareholders letter, Dr. Matt Coffey, President & CEO of Oncolytics Biotech, wrote: "I am pleased to report that we are well on our way to achieving these three objectives."

Back in April 2021, Oncolytics presented cohort data from its AWARE-1 study, being conducted with Roche, showing that the first two objectives referenced above had been achieved.

By December at the 2021 San Antonio Breast Cancer Symposium (SABCS), Oncolytics presented a positive safety update from its IRENE Phase 2 Triple-Negative Breast Cancer Trial evaluating the safety and efficacy of pelareorep in combination with the anti-PD-1 checkpoint inhibitor retifanlimab from Incyte for second- or third-line treatment of patients with metastatic triple-negative breast cancer (TNBC).

"Prior clinical studies have shown that pelareorep upregulates tumor PD-L1 expression and reverses immunosuppressive TMEs," said Mridula George, M.D., Medical Oncologist, Rutgers Cancer Institute of New Jersey, Assistant Professor of Medicine, Rutgers Robert Wood Johnson Medical School, and principal investigator of the trial. "These findings suggest that pelareorep can address a pressing unmet need in TNBC by synergizing with PD-1 inhibition to increase the proportion of patients responding to therapy. We look forward to evaluating this hypothesis through the IRENE study's continued advancement and are pleased that the pelareorep-retifanlimab combination has been well-tolerated in each of the patients enrolled in the trial."

Safety data from the trial showed the combination was well-tolerated, with no safety concerns noted in any of the patients enrolled in the trial at the time of reporting. The IRENE study remains ongoing and will continue to enroll patients at the Rutgers Cancer Institute of New Jersey and the Ohio State University Comprehensive Cancer Center.

Pull back and correction

 

Bull Markets, Pullbacks And Corrections By: Kevin Matras January 19, 2022

---

After a stellar run-up last year, it looks like we are starting this year off with 

a bit of a pullback.

And I, for one, couldn't be happier. 

Why? Because the 'fear' of a pullback was keeping plenty of investors on the sidelines.

And the sooner we can get this over with, the sooner we can get back to the bull market rally.

What's important to know is that pullbacks and corrections are common.

Every bull market has them.

In fact, stocks usually pull back about -5% roughly 3-4 times per year. 

(A pullback is defined as a decline between -5% and -9.99%.)

And we saw roughly 3 pullbacks last year for the Dow and the S&P, all while the markets went up 18.7% and 26.9% respectively.

Stocks usually correct -10% on average about once a year. (A decline of -10% to -19. Up 99% is called a correction.)

And we saw that with the Nasdaq last year too while finishing up 21.4%.

But these are the pauses that refresh before the next leg up.

Now the markets are at it again.

From the recent highs, the Dow at its worst has pulled back by -5.24%, the S&P by -5.99%, and the Nasdaq by -11.6%.

After shaking the tree, it will be exciting to see how high the market can go this time.

While pullbacks and corrections are never fun when they're happening, if you know these are commonplace moves, you can instead look at them as opportunities to buy rather than places to sell.

The only 3 things beginners need to focus on in the stock market. Day Tr...

Options Trading Explained - COMPLETE BEGINNERS GUIDE (Part 1)

SNAP

 

NKLA review

 Citation (MONDAY, JANUARY 10, 2022 | JEA YU MarketBeats)

Electric vehicle (EV) maker and hydrogen energy solutions firm Nikola (NASDAQ: NKLA)stock has seen a resurgence in recent events. Shares of the former SPAC took a dramatic sell-off on the ouster of its former CEO Trevor Milton and fraud allegations. However, the Company is rebuilding its reputation as it nears deliveries on its Nikola Tre BEV trucks. It is also in the process of settling civil fraud charges with the U.S. Securities and Enforcement Commission (SEC) for $125 million, which is 20% of cash on hand. Recently, Nikola announced deals for battery electric vehicles (BEVs) including the deal with USA Truck for 10 vehicles and with SAIA for 100 BEVs. The Company expects to deliver 25 vehicles in 2022 and up to 100 production vehicles by 2024. The Company expects profitability by 2025. Prudent investors seeking a potential turnaround play in clean energy and EVs can watch for opportunistic pullbacks in shares of Nikola.                                 

Q3 2021 Earnings Release 

On Nov. 3, 2021, NKLA released its fiscal third-quarter 2021 results for the quarter ending September 2021. The Company reported an EPS loss of (-$0.22) versus a loss of (-$0.38) consensus analyst estimates, a $0.16 beat. The Company is pre-revenues but managed to continue to grow its infrastructure building out a sales and service network of dealers in 28 states and over 130 locations. Nikola CEO Mark Russell commented,  "Validation of the Nikola Tre BEV is progressing, with trucks now being test-driven and tested on public roads. We also formally inaugurated our joint venture manufacturing facility in Ulm, Germany, and entered into additional strategic partnerships to advance our hydrogen refueling ecosystem with TC Energy and OPAL Fuels." CEO Russell added, "with prospects of an SEC settlement, we're looking forward to resolving the outstanding issues relating to our founder and bringing that chapter to a close and maintaining our focus on delivering trucks to our customers, and building the energy, service, and support infrastructure our customers need."

ROBLOX

 

OSAT

Y

 Orbsat 

• The Trade: Orbsat Corp. (NASDAQ: OSAT) Vice Chairman And Chief Business Development Strategist Douglas Ellenoff acquired a total of 46297 shares at an average price of $3.24. The insider spent $150,002.28 to buy those shares.
• What's Happening: Orbsat recently reported a $7.2 million private placement.
• What Orbsat Does: Orbsat Corp provides satellite-based asset tracking and monitoring services which also includes ground station construction, product design, and engineering services.

Man Who Predicted 2020 Crash Warns of Huge Event in 2022

Man Who Predicted 2020 Crash Warns of Huge Event in 2022

Marc Chaikin’s newest prediction has gone viral, with 1.5 million views.

According to Chaikin, who spent 50 years on Wall Street, a historic event in 2022 will cause a massive shift in the wealth divide.

“This will affect anyone who owns stocks,” says Chaikin, who accurately predicted the 2020 Crash. “Most people will never see it coming, for the simple and sad reason that nobody wants this to happen. Nobody.”

Chaikin predicts a new form of technology will disrupt everything.

“This is all a direct result of 2020,” he adds.

Chaikin – a popular guest on Jim Cramer’s Mad Money – has never shied away from sharing his controversial predictions.

Famously, he once predicted the collapse of Priceline.com in a debate on CNBC. When the stock went on to collapse 100 points overnight, his opponent took to the air the next day to admit that Chaikin was right.

Now, Chaikin is pointing to a huge change in the way thousands of companies will need to do business in 2022.

GoCo